Significantly lower annual rates of neoplastic progression in short- compared to long-segment non-dysplastic Barrett’s esophagus: a systematic review and meta-analysis

Abstract

Background Although shorter lengths of Barrett’s esophagus (BE) have been associated with a lower risk of neoplastic progression, precise estimates have varied, especially for non-dysplastic BE (NDBE) only. Therefore, current US guidelines do not provide specific recommendations on surveillance intervals based on BE length. We performed a systematic review and meta-analysis of the published literature to examine neoplastic progression rates of NDBE based on BE length.

Methods PubMed, Cochrane, Google Scholar, and Embase were comprehensively searched. Studies reporting progression rates in patients with NDBE and > 1 year of follow-up were included. The number of patients progressing to esophageal adenocarcinoma (EAC) and high grade dysplasia (HGD)/EAC in individual studies and the mean follow-up were recorded to derive person-years of follow-up. Pooled rates of progression to EAC and HGD/EAC based on BE length (< 3 cm vs. ≥ 3 cm) were calculated.

Results Of the 486 initial studies identified, 10 met the inclusion/exclusion criteria. These included a total of 4097 NDBE patients; 1979 with short-segment BE (SSBE; 10 773 person-years of follow-up) and 2118 with long-segment BE (LSBE; 12 868 person-years). The annual rates of progression to EAC were significantly lower for SSBE compared with LSBE: 0.06 % (95 % confidence interval 0.01 % – 0.10 %) vs. 0.31 % (0.21 % – 0.40 %), respectively; odds ratio (OR) 0.25 (0.11 – 0.56); P < 0.001, as were the rates for the combined endpoint (HGD/EAC): 0.24 % (0.09 % – 0.32 %) vs. 0.76 % (0.43 % – 0.89 %), respectively; OR 0.35 (0.21 – 0.58); P < 0.001. There was no significant heterogeneity among studies.

Conclusion The results demonstrate significantly lower rates of neoplastic progression in NDBE patients with SSBE compared with LSBE. BE length can easily be used for risk stratification purposes for NDBE patients undergoing surveillance endoscopy and consideration should be given to tailoring surveillance intervals based on BE length in future US guidelines.

• References

• 1 Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol 1999; 26: 2-8
• 2 Vizcaino AP, Moreno V, Lambert R. et al. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973–1995. Int J Cancer 2002; 99: 860-868
• 3 Botterweck AA, Schouten LJ, Volovics A. et al. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 2000; 29: 645-654
• 4 Lord RV, Law MG, Ward RL. et al. Rising incidence of oesophageal adenocarcinoma in men in Australia. J Gastroenterol Hepatol 1998; 13: 356-362
• 5 Howlader N, Noone AM, Krapcho M. et al. eds. SEER Cancer Statistics Review, 1975–2014. (based on November 2016 SEER data submission, posted to the SEER website, April 2017) National Cancer Institute, Bethesda, MD. Available from: https://seer.cancer.gov/csr/1975_2014/ (Accessed: 1 March 2019)
• 6 Hvid-Jensen F, Pedersen L, Drewes AM. et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. NEJM 2011; 365: 1375-1383
• 7 Kastelein F, van Olphen S, Steyerberg EW. et al. ProBarstudy group. Surveillance in patients with long-segment Barrett’s oesophagus: a cost-effectiveness analysis. Gut 2015; 64: 864-871
• 8 Inadomi JM, Sampliner R, Lagergren J. et al. Screening and surveillance for Barrett esophagus in high-risk groups: a cost–utility analysis. Ann Intern Med 2003; 138: 176-186
• 9 Sikkema M, de Jonge PJ, Steyerberg EW. et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010; 8: 235-244
• 10 Desai TK, Krishnan K, Samala N. et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012; 61: 970-976
• 11 Yousef F, Cardwell C, Cantwell MM. et al. The incidence of esophageal cancer and high-grade dysplasia in Barrettʼs esophagus: a systematic review and meta-analysis. Am J Epidemiol 2008; 168: 237-249
• 12 Thomas T, Abrams KR, De Caestecker JS. et al. Meta analysis: Cancer risk in Barrettʼs oesophagus. Aliment Pharmacol Therap 2007; 26: 1465-1477
• 13 Fitzgerald RC, di Pietro M, Ragunath K. et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrettʼs oesophagus. Gut 2014; 63: 7-42
• 14 Spechler SJ, Sharma P, Souza RF. et al. American Gastroenterological Association medical position statement on the management of Barrettʼs esophagus. Gastroenterology 2011; 140: 1084-1091
• 15 Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrettʼs esophagus. Am J Gastroenterol 2008; 103: 788-797
• 16 Shaheen NJ, Falk GW, Iyer PG. et al. ACG Clinical Guideline: Diagnosis and management of Barrettʼs esophagus. Am J Gastroenterol 2016; 111: 30-50
• 17 Anaparthy R, Gaddam S, Kanakadandi V. et al. Association between length of Barrettʼs esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia. Clin Gastroenterol Hepatol 2013; 11: 1430-1436
• 18 Pereira AD, Chaves P. Low risk of adenocarcinoma and high-grade dysplasia in patients with non-dysplastic Barrettʼs esophagus: Results from a cohort from a country with low esophageal adenocarcinoma incidence. United European Gastroenterol J 2016; 4: 343-352
• 19 Liberati A, Altman DG, Tetzlaff J. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLOS Medicine 2009; 6: e1000100
• 20 Weston AP, Krmpotich PT, Cherian R. et al. Prospective long-term endoscopic and histological follow-up of short segment Barrett’s esophagus: comparison with traditional long segment Barrett’s esophagus. Am J Gastroenterol 1997; 92: 407-413
• 21 Bowers SP, Mattar SG, Smith CD. et al. Clinical and histologic follow-up after antireflux surgery for Barrettʼs esophagus. J Gastrointest Surg 2002; 6: 532-538
• 22 Conio M, Blanchi S, Lapertosa G. et al. Long-term endoscopic surveillance of patients with Barrett’s esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 2003; 98: 1931-1939
• 23 Basu KK, Pick B, de Caestecker JS. Audit of a Barrett’s epithelium surveillance database. Eur J Gastroenterol Hepatol 2004; 16: 171-175
• 24 Vieth M, Schubert B, Lang-Schwarz K. et al. Frequency of Barrett’s neoplasia after initial negative endoscopy with biopsy: a long-term histopathological follow-up study. Endoscopy 2006; 38: 1201-1205
• 25 Biertho L, Dallemagne B, Dewandre JM. et al. Laparoscopic treatment of Barrett’s esophagus: long-term results. Surg Endosc 2007; 21: 11-15
• 26 Martinek J, Benes M, Brandtl P. et al. Low incidence of adenocarcinoma and high-grade intraepithelial neoplasia in patients with Barrett’s esophagus: a prospective cohort study. Endoscopy 2008; 40: 711-716
• 27 Rugge M, Zaninotto G, Parente P. et al. Barrett’s esophagus and adenocarcinoma risk: the experience of the North-Eastern Italian Registry (EBRA). Ann Surg 2012; 256: 788-794
• 28 Hamade N, Vennelaganti S, Parasa S. et al. Lower annual rate of progression of short-segment vs long-segment Barrett’s esophagus to esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2018;
• 29 Pohl H, Pech O, Arash H. et al. Length of Barrett’s oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinoma. Gut 2016; 65: 196-201
• 30 Thota PN, Vennalaganti P, Vennalaganti S. et al. Low risk of high-grade dysplasia or esophageal adenocarcinoma among patients with Barrett’s esophagus less than 1 cm (Irregular Z-line) within 5 years of index endoscopy. Gastroenterology 2017; 152: 987-992
• 31 Krishnamoorthi R, Singh S, Ragunathan K. et al. Factors associated with progression of Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2018; 16: 1046-1055
• 32 Schoofs N, Bisschops R, Prenen H. Progression of Barrett’s esophagus towards esophageal adenocarcinoma: an overview. Ann Gastroenterol 2017; 30: 1-6
• 33 Han S, Wani S. Quality indicators in Barrett's esophagus: time to change the status quo. Clin Endosc 2018; 51: 344-351